Benedict Financial Advisors Inc. Has $6.97 Million Stake in Johnson & Johnson (JNJ)

Benedict Financial Advisors Inc. cut its position in Johnson & Johnson (NYSE:JNJ) by 1.4% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 53,586 shares of the company’s stock after selling 767 shares during the quarter. Johnson & Johnson accounts for 3.6% of Benedict Financial Advisors Inc.’s portfolio, making the stock its 2nd biggest holding. Benedict Financial Advisors Inc.’s holdings in Johnson & Johnson were worth $6,967,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Harding Loevner LP acquired a new position in Johnson & Johnson during the 2nd quarter valued at about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its stake in Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. boosted its stake in Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares during the last quarter. IHT Wealth Management LLC boosted its stake in Johnson & Johnson by 46.4% during the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after purchasing an additional 3,467 shares during the last quarter. Finally, Mountain Capital Investment Advisors Inc acquired a new position in Johnson & Johnson during the 2nd quarter valued at about $124,000. Institutional investors own 65.70% of the company’s stock.

Shares of Johnson & Johnson (JNJ) opened at $144.14 on Wednesday. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The company has a market cap of $387,230.00, a P/E ratio of 25.02, a P/E/G ratio of 2.67 and a beta of 0.80. Johnson & Johnson has a 1-year low of $110.76 and a 1-year high of $145.68.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. The company had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. Johnson & Johnson’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.68 EPS. analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.33%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.

A number of equities analysts have issued reports on the company. Piper Jaffray Companies reiterated a “hold” rating and set a $120.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 4th. Vetr downgraded Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 price target for the company. in a research note on Monday, September 18th. Stifel Nicolaus lifted their price target on Johnson & Johnson from $140.00 to $142.00 and gave the company a “hold” rating in a research note on Wednesday, October 18th. Wells Fargo & Co upgraded Johnson & Johnson from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $140.00 to $149.00 in a research note on Monday, October 9th. Finally, JPMorgan Chase & Co. downgraded Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 2nd. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $145.52.

TRADEMARK VIOLATION WARNING: This piece of content was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was stolen and reposted in violation of US & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/01/10/benedict-financial-advisors-inc-has-6-97-million-stake-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit